Lv2
198 积分 2023-11-09 加入
Exploratory phase II trial of an anti-PD-1 antibody camrelizumab combined with a VEGFR-2 inhibitor apatinib and chemotherapy as a neoadjuvant therapy for triple-negative breast cancer (NeoPanDa03): efficacy, safety and biomarker analysis
10分钟前
待确认
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
1小时前
已完结
Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study
26天前
已完结
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
1个月前
已完结
Computed tomography density changes of bone metastases after concomitant denosumab
1个月前
已完结
Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer
1个月前
已完结
Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4
1个月前
已完结
Bone metastases
1个月前
已完结
Ribociclib plus Endocrine Therapy in Early Breast Cancer
1个月前
已关闭
中国乳腺癌抗体药物偶联物安全性管理专家共识
1个月前
已完结
皖公网安备34019202002308
